Burkitt Lymphoma Clinical Trial
Official title:
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01943682 -
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
|
Phase 1 | |
| Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT05020392 -
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
|
Phase 3 | |
| Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
| Terminated |
NCT03864419 -
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
|
Phase 1 | |
| Terminated |
NCT02700022 -
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
|
Phase 1 | |
| Completed |
NCT00849147 -
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
|
Phase 2 | |
| Completed |
NCT00822432 -
Coproporphyrine Isomers and Methotrexate Elimination
|
N/A | |
| Recruiting |
NCT00180882 -
LMBA02 Protocol for Patients With a Burkitt Lymphoma
|
Phase 3 | |
| Recruiting |
NCT06060782 -
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
|
Phase 1 | |
| Active, not recruiting |
NCT02996773 -
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
|
Phase 1 | |
| Recruiting |
NCT05565417 -
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03298828 -
CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
|
Phase 1 | |
| Completed |
NCT01290120 -
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT00719888 -
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
|
Phase 2 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Recruiting |
NCT04425421 -
Recommendations for the Treatment of Children With Burkitt's Lymphoma
|
||
| Active, not recruiting |
NCT00001337 -
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05518383 -
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
|
Phase 4 | |
| Terminated |
NCT01028716 -
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 |